Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- New Rules for Application of GCP Ordinance to Take Effect April 1, 2012
October 25, 2011
- EMA Confirms Usefulness of Pioglitazone-Containing Medicines as 2nd, 3rd Line Treatment Options: Takeda
October 24, 2011
- Survey Finds Slight Increase in Generic Drug Dispensing Rate
October 24, 2011
- Korosho Receives 270 Requests for Development of Unapproved Drugs, Indications in 2nd Round
October 24, 2011
- Groups of Care Providers, Patients Against Creating Compensation System for Injury from Anticancer Drugs
October 22, 2011
- Drug Discovery Support Agency Will Not Compete with Private Sector: Mr Tsuchiya
October 21, 2011
- CSIMC Recommended Approval for Reimbursement on Piecework for 2 High-Priced Drugs
October 21, 2011
- Survey Finds Slight Increase in Generic Drug Dispensing Rate
October 21, 2011
- MHLW to Review Premium System Placing Priority on Premium for Pediatric Use
October 20, 2011
- Mr Kobayashi of Chuikyo Insists on NHI Price Reductions for New Generics
October 20, 2011
- MHLW Subcommittee Agrees on Access System for Domestically Unapproved Drugs
October 20, 2011
- MHLW Presents Data at Chuikyo Supporting Reduction in 70% Rule for New Generics
October 20, 2011
- Cost of Advanced Healthcare Services Totaled ¥13.2 Billion in FY2010: Korosho
October 20, 2011
- HSC Subcommittee Considering Review of Refractory Diseases Eligible for Treatment Subsidies
October 20, 2011
- MHLW Revises Precautions for Use in OTC Drugs
October 19, 2011
- PMDA Presents Warnings on Website to Prevent Mistaken Use of 3 Taxane Drugs
October 19, 2011
- Korosho Proposes 80% Price Rule for Single-enantiomer Drugs
October 19, 2011
- Korosho Presents Direction for PAL Amendment in 2012
October 19, 2011
- Council to Set Up Committee to Discuss Creation of “Drug Discovery Support Organization”
October 18, 2011
- MHLW to Survey, Consider Measures for Clinical Trials in Coping with Earthquakes
October 17, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…